Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

Detalhes bibliográficos
Autor(a) principal: Marques, Catarina
Data de Publicação: 2014
Outros Autores: Mega, Cristina, Gonçalves, Andreia, Rodrigues-Santos, Paulo, Lemos, Edite Teixeira de, Teixeira, Frederico, Fontes-Ribeiro, Carlos A., Reis, F., Fernandes, Rosa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/109506
https://doi.org/10.1155/2014/538737
Resumo: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.
id RCAP_0a10ce8e77ff5124542626efc60fb413
oai_identifier_str oai:estudogeral.uc.pt:10316/109506
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsAnimalsApoptosisDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1InflammationKidneyPyrazinesRatsRats, ZuckerSitagliptin PhosphateTriazolesTumor Necrosis Factor-alphaThis study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.Hindawi2014info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/109506http://hdl.handle.net/10316/109506https://doi.org/10.1155/2014/538737eng0962-93511466-1861Marques, CatarinaMega, CristinaGonçalves, AndreiaRodrigues-Santos, PauloLemos, Edite Teixeira deTeixeira, FredericoFontes-Ribeiro, Carlos A.Reis, F.Fernandes, Rosainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-10-18T09:39:40Zoai:estudogeral.uc.pt:10316/109506Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:25:41.535231Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
title Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
spellingShingle Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
Marques, Catarina
Animals
Apoptosis
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
Inflammation
Kidney
Pyrazines
Rats
Rats, Zucker
Sitagliptin Phosphate
Triazoles
Tumor Necrosis Factor-alpha
title_short Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
title_full Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
title_fullStr Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
title_full_unstemmed Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
title_sort Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
author Marques, Catarina
author_facet Marques, Catarina
Mega, Cristina
Gonçalves, Andreia
Rodrigues-Santos, Paulo
Lemos, Edite Teixeira de
Teixeira, Frederico
Fontes-Ribeiro, Carlos A.
Reis, F.
Fernandes, Rosa
author_role author
author2 Mega, Cristina
Gonçalves, Andreia
Rodrigues-Santos, Paulo
Lemos, Edite Teixeira de
Teixeira, Frederico
Fontes-Ribeiro, Carlos A.
Reis, F.
Fernandes, Rosa
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Marques, Catarina
Mega, Cristina
Gonçalves, Andreia
Rodrigues-Santos, Paulo
Lemos, Edite Teixeira de
Teixeira, Frederico
Fontes-Ribeiro, Carlos A.
Reis, F.
Fernandes, Rosa
dc.subject.por.fl_str_mv Animals
Apoptosis
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
Inflammation
Kidney
Pyrazines
Rats
Rats, Zucker
Sitagliptin Phosphate
Triazoles
Tumor Necrosis Factor-alpha
topic Animals
Apoptosis
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
Inflammation
Kidney
Pyrazines
Rats
Rats, Zucker
Sitagliptin Phosphate
Triazoles
Tumor Necrosis Factor-alpha
description This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/109506
http://hdl.handle.net/10316/109506
https://doi.org/10.1155/2014/538737
url http://hdl.handle.net/10316/109506
https://doi.org/10.1155/2014/538737
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0962-9351
1466-1861
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Hindawi
publisher.none.fl_str_mv Hindawi
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134138889928704